An Introduction to Breast Cancer
New perspectives in cancer therapy have led to rapid progress in breast cancer research. Some of the most exciting recent developments include ongoing studies aiming to enhance current breast cancer screening options, as well as approval of several poly-ADP ribose polymerase (PARP) inhibitors. Other areas of active research include histone deacetylase (HDAC) inhibitors and chimeric antigen receptor (CAR) T-cell therapies.
Browse our selection of video highlights and short articles from the conference hub, which provide insights into the latest updates from major conferences, and a collection of peer-reviewed articles from the journal portfolio. These are complemented by a range of educational activities from our expert faculty, with patient outcomes at the forefront.
Our supporting partners do not constitute an endorsement of the content on this page.
Breast Cancer Content
Aditya Bardia, SABCS 2021: Results of EMERALD Phase III Trial
Dr Aditya Bardia (Harvard Medical School, Boston, MA, USA) discusses the results of the phase III EMERALD trial, exploring elacestrant, an oral selective estrogen receptor degrader, vs investigator’s choice of endocrine monotherapy for ER+/HER2- advanced/metastatic breast cancer following progression on prior endocrine and CDK4/6 inhibitor therapy. These results were presented at the San Antonio Breast […]
Nancy Lin, SABCS 2021: Updated Results of the HER2CLIMB Study
Dr Nancy Lin (Dana-Farber Cancer Institute, Boston, MA, USA) discusses the updated results of the phase II HER2CLIMB study, which assessed tucatinib vs placebo added to trastuzumab and capecitabine for patients with previously treated HER2-positive metastatic breast cancer with brain metastases. These results were presented at the San Antonio Breast Cancer Symposium 2021. Questions 1. […]
Marta Vaz Batista, SABCS 2021: Preliminary Results From the DEBBRAH Phase II Study
Dr Marta Vaz Batista (Hospital Fernando Fonseca, Amadora, Portugal) discusses the preliminary results from the DEBBRAH phase II study, exploring trastuzumab deruxtecan in patients with HER2[+] or HER2-low-expressing advanced breast cancer and central nervous system involvement. These results were presented at the San Antonio Breast Cancer Symposium 2021. Questions 1. Could you tell us a […]
David Potter, SABCS 2021: Results From the I-SPY 2 Trial
Professor David Potter (Masonic Cancer Center, University of Minnesota, Minneapolis, MN, USA) discusses the results of the I-SPY 2 trial, the evaluation of tucatinib + (paclitaxel + pertuzumab + trastuzumab) in high-risk HER2 positive stage II/III breast cancer. These results were presented at the San Antonio Breast Cancer Symposium 2021. Question: Please can you summarise […]
Sara Hurvitz, SABCS 2021: Efficacy and Safety Findings of the coopERA Study
Professor Sara Hurvitz (David Geffen School of Medicine at UCLA, Los Angeles, CA, USA) discusses her presentation at the San Antonio Breast Cancer Symposium 2021 on the aims, efficacy and safety findings of the coopERA study. Questions 1. What is giredestrant, and what is the rationale for its use in HR+, HER2− early breast cancer? […]
Sara Hurvitz, SABCS 2021: Efficacy and Safety Findings of the TRINITI-1 Study
Professor Sara Hurvitz (David Geffen School of Medicine at UCLA, Los Angeles, CA, USA) discusses her presentation at the San Antonio Breast Cancer Symposium 2021 on the aims, efficacy and safety findings of the TRINITI-1 study. Questions 1. What are the major unmet needs in the treatment of women with HR+, HER2− breast cancer? 00:12-02:06 […]
A New Standard of Care: Pembrolizumab in Programmed Death-ligand 1 Positive, Metastatic, Triple-negative Breast Cancer
touchREVIEWS in Oncology & Haematology. 2021;17(2):Online ahead of publication
Cumulatively, TNBC accounts for 35–40% of breast cancer deaths in the United States, despite only comprising 10–15% of total breast cancer cases diagnosed.1 Even before the use of anti-estrogen therapies became widespread, hormone receptor-positive breast cancer (HR+BC) provided a far more favourable risk of recurrence and overall prognosis compared with TNBC.2,3 Once metastatic, TNBC historically carries […]
Javier Cortés, ESMO 2021: Results of the Randomized Phase III DESTINY-Breast03 Study
touchONCOLOGY joins Dr Javier Cortés at ESMO 2021 to discuss the much-anticipated results of the randomized phase III DESTINY-Breast03 study. Questions 1. Why are antibody-drug conjugates needed in the treatment of HER2+ metastatic breast cancer? (00:17-01:17) 2. What were the objectives of the phase III DESTINY-Breast03 study? (01:17-01:55) 3. Could you tell us a little […]
Pathologic Complete Response as a Surrogate Endpoint in Breast Cancer
touchREVIEWS in Oncology & Haematology. 2021;17(1):12-7 DOI: https://doi.org/10.17925/OHR.2021.17.1.12
The metastatic setting has traditionally been the initial venue for the development of new drugs in breast cancer. This seems like a natural population in which to start because patients have often exhausted the armamentarium of approved agents and, therefore, clinical equipoise is easier to achieve. These trials, however, often involve sicker patients who can […]
Journal articles and more to your inbox
Get the latest clinical insights from touchONCOLOGYSign me up!